Core Viewpoint - Huazhong Securities report indicates that Kailaiying achieved a net profit attributable to shareholders of 800 million yuan in the first three quarters of 2025, representing a year-on-year growth of 12.66%. However, the net profit for Q3 alone was 183 million yuan, showing a year-on-year decline of 13.46% [1] Financial Performance - In Q3 2025, the company's performance experienced slight fluctuations primarily due to the impact of order delivery schedules. It is expected that the delivery scale in Q4 will significantly exceed that of Q3 based on the distribution of pending orders from the second half of the year [1] - The company maintains its full-year performance guidance, projecting an annual revenue growth of 13%-15% [1] Order and Business Growth - In Q3 2025, the company signed new orders with double-digit growth, which has improved compared to the growth rate in the first half of the year. The new business segments, including chemical macromolecules and biological macromolecules, have shown strong growth in new orders [1] Capital Expenditure Plans - The company plans to increase its capital expenditure significantly, raising the expected amount for 2025 to 1.3-1.4 billion yuan, primarily focusing on emerging business areas. Capital expenditure is expected to further increase in 2026 [1] Profitability Outlook - Given that the current gross margin level of emerging businesses is relatively low, an increase in revenue share from these areas is anticipated to lower the overall gross margin of the company. Consequently, the profit forecasts for 2025-2027 have been revised downward [1] - The company maintains a "Buy" rating despite the adjustments to profit forecasts [1]

Core Viewpoint - The company, Kailaiying Pharmaceutical Group, reported a significant increase in revenue and operational efficiency in the third quarter of 2025, driven by growth in emerging business sectors and a positive outlook for the pharmaceutical industry [3]. Financial Performance - In the first three quarters of 2025, the company achieved total revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82% [3]. - Revenue from emerging businesses increased by 71.87%, while revenue from chemical macromolecule businesses grew by over 150% [3]. - Revenue from large pharmaceutical companies was 2.05 billion yuan, up 1.98%, and revenue from small and medium-sized pharmaceutical companies reached 2.58 billion yuan, up 21.14% [3]. - The overall gross profit margin for the company was 42.44%, with the gross profit margin for emerging businesses improving by 10.57 percentage points to 30.55% [3]. Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter, projecting an annual revenue growth of 13% to 15% [3].

Financing and Strategic Partnerships - Vanke A has signed a framework agreement with its largest shareholder, Shenzhen Metro Group, to provide a loan limit of up to 22 billion yuan [3] - Betta Pharmaceuticals has reached a strategic cooperation with Shengsi Biotech, obtaining exclusive distribution rights for a long-acting recombinant factor VIII product in Greater China [4] - Nenghui Technology has established a joint venture with Zhejiang Lisan, investing 10 million yuan to capitalize on opportunities in the "computing power + AI" and "computing power + new energy" sectors [6] Market Performance - Seres reported a total vehicle sales of 54,384 units in October 2025, with new energy vehicle sales reaching 51,456 units, marking a year-on-year increase of 42.89% [9] - BAIC Blue Valley's subsidiary achieved a 112.02% year-on-year increase in sales for October 2025, totaling 30,542 units [10] - Changan Automobile's new energy vehicle sales grew by 36.14% year-on-year in October 2025, with total sales of 278,400 units for the month [12] - Great Wall Motors reported October sales of 143,100 units, reflecting a year-on-year increase of 22.5% [13] - BYD exported a total of 83,904 new energy vehicles in October 2025, with a total battery installation capacity of approximately 27.362 GWh for the month [14] Shareholding Changes - Jintai Technology's shareholder, Gaoxin Investment, plans to reduce its stake by up to 3% through various trading methods [16] - Yongzhen Co., Ltd. announced that two shareholders intend to reduce their holdings by up to 3% [17] - Huafeng Measurement Control's controlling shareholder plans to reduce its stake by up to 2% [18] - Rongqi Technology's employee strategic placement asset management plan intends to reduce its holdings by up to 1.32% [19] - Jinli Permanent Magnet's directors and senior management plan to collectively reduce their holdings by up to 0.15% [20] Major Contracts - ST Yifei signed an overseas procurement order worth approximately 190 million yuan, accounting for 27.46% of its audited revenue for 2024 [21] - Lanjian Intelligent signed a daily operational contract worth 138 million yuan [22] - Jingye Intelligent won a bid for a process equipment project valued at 134 million yuan [23] - Daye Intelligent's subsidiary signed a bareboat charter contract for two vessels, with total rental income projected at approximately 48.73 million USD over 1,095 days [24]

智通财经APP获悉，香港联交所最新资料显示，10月28日，Schroders PLC增持凯莱英(06821)8.74万股， 每股作价88.3138港元，总金额约为771.86万港元。增持后最新持股数目约为607.39万股，持股比例为 22.04%。 ...

Core Viewpoint - Morgan Stanley has reduced its stake in Kelaiying (06821) by 19,400 shares at a price of HKD 88.2767 per share, totaling approximately HKD 1.7126 million, resulting in a new holding of about 2.1962 million shares, representing 7.97% of the company [1] Summary by Category - **Shareholding Changes** - Morgan Stanley sold 19,400 shares of Kelaiying on October 28 [1] - The sale price was HKD 88.2767 per share, amounting to approximately HKD 1.7126 million [1] - After the reduction, Morgan Stanley's remaining shares are approximately 2.1962 million, which is 7.97% of the total shares [1]

Group 1 - Morgan Stanley reduced its stake in Kelaiying (002821)(06821) by 19,400 shares at a price of HKD 88.2767 per share, totaling approximately HKD 1.7126 million [1] - After the reduction, Morgan Stanley's latest holding is approximately 2.1962 million shares, representing a holding percentage of 7.97% [1]

香港联交所最新资料显示，10月28日，Schroders PLC增持凯莱英（002821）(06821)8.74万股，每股作价 88.3138港元，总金额约为771.86万港元。增持后最新持股数目约为607.39万股，持股比例为22.04%。 ...

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]

Financial Performance - Revenue reached 4.63 billion RMB, an increase of 11.8% compared to the previous year [5] - Gross profit margin is at 42.4%, with a slight decrease of 1.2 percentage points [5] - Net profit attributable to shareholders is 800 million RMB, reflecting a growth of 12.7% [5] - Net profit margin increased by 0.1 percentage points to 17.3% [5] Business Segments - Small molecule CDMO business revenue remained stable with a gross margin of 47.0% [5] - Emerging business revenue surged by 71.9%, with a gross margin of 30.6% [5] - Chemical macromolecule business revenue grew by over 150% year-on-year [5] - Emerging business gross margin improved by 10.6 percentage points compared to the same period last year [5] Market Trends - Continuous market expansion in peptide, oligonucleotide, and ADC segments, with new orders maintaining double-digit growth [6] - Anticipated annual revenue growth of 13%-15% based on order distribution for the second half of the year [6] Customer Revenue Breakdown - Revenue from small pharmaceutical companies increased by 2.0% [10] - Revenue from multinational pharmaceutical companies (excluding large orders) grew by 21.1% [10] Expense Ratios - Sales expenses as a percentage of revenue decreased from 4.2% in 2024 Q1-Q3 to 4.0% in 2025 Q1-Q3 [12] - Management expenses as a percentage of revenue decreased from 14.2% in 2024 Q1-Q3 to 12.6% in 2025 Q1-Q3 [14] - R&D expenses as a percentage of revenue increased from 9.0% in 2023 to 11.7% in 2024 Q1-Q3 [16] Capital Expenditure - Capital expenditure for Q1-Q3 was reported at 8.38 million RMB [25]

Group 1: Company Performance Overview - The company achieved double-digit growth in new orders for Q3, with an acceleration compared to the first half of the year [2] - The new business segments, including chemical and biological macromolecule businesses, are showing strong growth, indicating a positive revenue outlook for 2026 [2] Group 2: Capacity and Capital Expenditure - The capital expenditure for 2025 is projected to increase to approximately 1.3-1.4 billion, focusing on new business areas [3] - The small molecule business is experiencing tight capacity, particularly in Tianjin, while the Northeast facility is operating at normal utilization levels [3] - The company is expanding its capacity in the chemical macromolecule sector, with significant growth expected in the peptide and oligonucleotide businesses [3] Group 3: Profitability and Margins - The gross margin for new business segments reached 30.6% in the first three quarters of 2025, an increase of 10.6 percentage points year-on-year [4] - The domestic business revenue is expected to continue increasing, driven by a competitive domestic market and ongoing projects [5] - The company is implementing cost control measures to ensure that expense growth remains below revenue growth [6] Group 4: Market Trends and Future Outlook - The company anticipates a revenue growth of 13%-15% for the full year 2025, with increasing growth rates expected in 2026 and 2027 [4] - The domestic revenue share is expected to rise, supported by the increasing number of projects going overseas [5] - The company is focusing on enhancing its capabilities to capture more collaboration opportunities in the rapidly growing new molecule sector [4] Group 5: Competitive Positioning - The company’s core competencies lie in its delivery capabilities and investment in new technologies aimed at significantly reducing production costs [7] - The revenue structure of the chemical macromolecule business shows over 50% coming from peptide business, with a shift towards overseas markets expected [8]